...
首页> 外文期刊>Journal of Alzheimer's disease: JAD >Alzheimer's Disease: A Journey (f)rom Amyloid Peptides and Oxidative Stress, to Biomarker Technologies and Disease Prevention Strategies-Gains from AIBL and DIAN Cohort Studies
【24h】

Alzheimer's Disease: A Journey (f)rom Amyloid Peptides and Oxidative Stress, to Biomarker Technologies and Disease Prevention Strategies-Gains from AIBL and DIAN Cohort Studies

机译:阿尔茨海默病:旅程(F)淀粉样肽和氧化应激,来自AIBL和Dian队列研究的生物标志物技术和疾病预防策略 - 收益

获取原文
获取原文并翻译 | 示例
           

摘要

Worldwide there are over 46 million people living with dementia, and this number is expected to double every 20 years reaching about 131 million by 2050. The cost to the community and government health systems, as well as the stress on families and carers is incalculable. Over three decades of research into this disease have been undertaken by several research groups in Australia, including work by our original research group in Western Australia which was involved in the discovery and sequencing of the amyloid-beta peptide (also known as A beta or A4 peptide) extracted from cerebral amyloid plaques. This review discusses the journey from the discovery of the A beta peptide in Alzheimer's disease (AD) brain to the establishment of pre-clinical AD using PET amyloid tracers, a method now serving as the gold standard for developing peripheral diagnostic approaches in the blood and the eye. The latter developments for early diagnosis have been largely achieved through the establishment of the Australian Imaging Biomarker and Lifestyle research group that has followed 1,100 Australians for 11 years. AIBL has also been instrumental in providing insight into the role of the major genetic risk factor apolipoprotein E epsilon 4, as well as better understanding the role of lifestyle factors particularly diet, physical activity and sleep to cognitive decline and the accumulation of cerebral A beta.
机译:全球范围内有超过4600万人患有痴呆症,预计每20年的每20多年的人数将增加每2050年。社区和政府卫生系统的成本以及家庭和护理人员的压力是不可估算的。在澳大利亚的几个研究小组中,在澳大利亚的几个研究小组上进行了三十年的研究,包括我们在西澳大利亚州的原始研究组的工作,该研究组参与了淀粉样蛋白β肽的发现和测序(也称为β或A4肽从脑淀粉样斑块中提取。本综述讨论了使用宠物淀粉样器示踪剂在阿尔茨海默病(AD)疾病(AD)疾病(AD)疾病中的β肽(AD)脑卒中的旅程中的旅程,该方法是现在作为在血液中开发外周诊断方法的金标准的方法眼睛。正在澳大利亚成像生物标志物和生活方式研究组随访1,100澳大利亚人持续11年来,已经大大实现了早期诊断的后一种发展。 AIBL也有助于深入了解主要遗传危险因素载体E epsilon 4的作用,以及更好地理解生活方式因素特别饮食,身体活动和睡眠以认知下降和脑β积累的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号